This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.
Luspatercept Improves Response Rates, Transfusion Independence for Lower-Risk MDS
Long-Term Data Support Teclistamab in Relapsed, Refractory Myeloma
Outpatient CAR T-Cell Therapy May Be Safe, Feasible for Relapsed/Refractory Non-Hodgkin Lymphoma
ASCO Offers an ‘Eye-Opening Experience’ for Nurse Practitioners
2 Commerce Drive
Cranbury, NJ 08512